Protagonist Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Dinesh V. Patel
- Full Time Employees
- 141
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 7707 Gateway Boulevard Newark CA United States of America 94560
- IPO Date
- Aug 11, 2016
- CIK
- 0001377121
- Website
- protagonist-inc.com
- Similar Companies
- Business
- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) is a clinical-stage biopharmaceutical company that develops novel peptide-based therapeutics targeting unmet needs in hematology, blood disorders, inflammatory, and immunomodulatory diseases. The company leverages a proprietary peptide technology platform, including molecular design tools such as Vectrix™, phage display libraries, oral stability assays, and advanced peptide chemistry, to engineer potent, selective peptides with oral bioavailability for targets like cytokines, receptors, transporters, GPCRs, and ion channels. Its lead product candidates include rusfertide (PTG-300), a hepcidin mimetic in Phase 3 (VERIFY trial) and Phase 2 extensions (REVIVE, THRIVE) for polycythemia vera; and the oral IL-23R antagonist JNJ-2113 (formerly PN-235 or PTG-200), partnered with Janssen (Johnson & Johnson), in Phase 3 for plaque psoriasis and Phase 2b (ANTHEM) for ulcerative colitis; alongside early-stage discovery programs like PN-477 (multi-receptor agonist for obesity), PN-881 (psoriasis), and others for hemochromatosis and hematologic diseases. Founded in 2006 and headquartered in Newark, California, Protagonist operates primarily in the United States with additional presence in Australia. Recent developments include positive Phase 3 data for icotrokinra (JNJ-2113) in plaque psoriasis driving a 32% stock surge in October 2025, plans for a New Drug Application submission for rusfertide in late 2025, advancement of early pipeline candidates with Phase 1 initiations targeted for Q4 2025, and ongoing acquisition discussions with Johnson & Johnson, which already holds a 4% equity stake and commercialization rights to certain assets.
Company News
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript
Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.
Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera
Bamco Inc. NY Makes New $1.96 Million Investment in Protagonist Therapeutics, Inc. $PTGX
Protagonist Therapeutics Reports Granting of Inducement Awards
Which Small-Cap ETF Is the Better Buy: iShares' Growth-Focused IWO or Invesco's Revenue-Weighted RWJ?
Protagonist Therapeutics: "Strong Buy" ICOTYDE FDA Approval And PN-881 Advancement
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
Which Growth ETF Is the Better Long-Term Buy: Vanguard's Mega Cap MGK or Invesco's Small-Cap RZG?
Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock
Protagonist Therapeutics (PTGX) Beats Q2 Earnings Estimates
Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Protagonist Therapeutics Reports Granting of Inducement Awards
Protagonist Therapeutics, Inc. $PTGX Stock Position Decreased by Bank of New York Mellon Corp
Fifth Third Bancorp Increases Stock Holdings in Protagonist Therapeutics, Inc. $PTGX
Protagonist Therapeutics Reports Granting of Inducement Awards
Best Momentum Stocks to Buy for July 13th
New Strong Buy Stocks for July 13th